Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study.
SourceBlood, 96, 1, (2000), pp. 63-70
Article / Letter to editor
Display more detailsDisplay less details
SubjectMolecular pathogenesis of multiple myeloma; Moleculaire pathogenese van het multipele myeloom loom (MM)
Recently the Belgium-dutch Hematology-Oncology group installed a multicenter study to evaluate a multicenter study to wether myeloma patients treated with intensive chemotherapy benefit rom additional perpheral stem cell transplantation. To determine treatment response accurately, we decided to quantitate malignant cells. To test a consensus qunatitation strategy, 5 centers independently determined the immunoglobulin heavy chain sequences of patient tumor cells and developed allele-specific oligonucleotides (ASO) and ASO-polymerase chain reaction (PCR). We compared the reproducibility of realtime quantitation with quantitation using limiting dilutions (4 centers), respectively. Within single centers we found an average variation coefficient of 0.74 with limiting dilutions not significantly different from the average 0.82 center-t0-center variation coefficient. Within a single center. real-time quantitation proved more reproducible (average variation coefficient 0.36). Quantification was comfirmed in 3 patients durign treatment in the protocol. This rep[ort shows that real-time PCR or limiting dilution assays can be used for quantitation in a single multicenter trial. We present consensus strategy that allows an accurate comparison of quantitation data genereted in independent centers.
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.